论文部分内容阅读
类风湿关节炎(RA)是一种高度致残性自身免疫性疾病,其治疗策略是早期诊断、早期给予改善病情抗风湿药(DMARDs)的联合治疗,以有效控制骨关节破坏,降低疾病活动度。近年来,造血干细胞移植、抗CD_2。单克隆抗体治疗难治性RA,均是缘于血液病治疗的成功经验。鉴于此,现代医学依据肿瘤联合化疗的基本理论——细胞增殖动力学原理,联合细胞周期特异性药物甲氨喋呤(MTX)与周期性非特异性药物环磷酰胺(CTX)小剂量按细胞增殖周期间歇给药治疗RA,回顾性
Rheumatoid arthritis (RA) is a highly disabling autoimmune disease whose treatment strategy is early diagnosis and early treatment with combination anti-rheumatic drugs (DMARDs) to effectively control the destruction of bone and joint joints and reduce disease activity degree. In recent years, hematopoietic stem cell transplantation, anti-CD_2. Monoclonal antibody treatment of refractory RA, are due to the successful experience of the treatment of blood diseases. In view of this, modern medicine based on the basic theory of tumor combined chemotherapy - the principle of cell proliferation kinetics, combined with the cell cycle-specific drugs methotrexate (MTX) and cyclophosphamide (CTX) low-dose cyclophosphamide Weekly intermittent treatment of RA, retrospective